Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | CFO AND TREASURER | June 22, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,876 |
Ending reported balance
After 2026-06-22 transaction · row 9
9 source rows · reconciled sequenceRow 1 · 2026-06-22 · Exercise / conversion · Acquired 8,750 · Balance 27,626 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Row 2 · 2026-06-22 · Sale · Disposed 164 · Balance 27,462 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2: This transaction was executed in multiple trades at prices ranging from $533.57 to $534.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-06-22 · Sale · Disposed 865 · Balance 26,597 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3: This transaction was executed in multiple trades at prices ranging from $534.57 to $535.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-06-22 · Sale · Disposed 1,091 · Balance 25,506 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F4: This transaction was executed in multiple trades at prices ranging from $535.64 to $536.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-06-22 · Sale · Disposed 840 · Balance 24,666 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F5: This transaction was executed in multiple trades at prices ranging from $536.65 to $537.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2026-06-22 · Sale · Disposed 2,266 · Balance 22,400 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6: This transaction was executed in multiple trades at prices ranging from $537.67 to $538.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2026-06-22 · Sale · Disposed 1,994 · Balance 20,406 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7: This transaction was executed in multiple trades at prices ranging from $538.67 to $539.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2026-06-22 · Sale · Disposed 280 · Balance 20,126 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8: This transaction was executed in multiple trades at prices ranging from $539.68 to $539.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 9 · 2026-06-22 · Sale · Disposed 1,250 · Balance 18,876 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $146.03 · Expires 2027-03-15 | Direct | 0 |
Reported balance
After 2026-06-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-06-22 · Exercise / conversion · Disposed 8,750 · Balance 0 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $533.57 to $534.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $534.57 to $535.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $535.64 to $536.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $536.65 to $537.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $537.67 to $538.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $538.67 to $539.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $539.68 to $539.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 10, 2025 Filed Nov 12, 2025 22:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,052 | $446.51 | $469,727.15 |
DisclosureSEC source: 0001636178-25-000005 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,066 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $445.81 to $446.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 22:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 21,000 | $146.03 | $3,066,630.00 |
DisclosureSEC source: 0001636178-25-000005 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 21,000 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001636178-25-000004 · primarydocument.xml · derivative · entry 11 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,312 Underlying: Common Stock · 21,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 120 | $439.51 | $52,741.22 |
DisclosureSEC source: 0001636178-25-000004 · primarydocument.xml · nonDerivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,118 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $439.37 to $439.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 360 | $438.50 | $157,859.50 |
DisclosureSEC source: 0001636178-25-000004 · primarydocument.xml · nonDerivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,238 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $438.34 to $438.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,752 | $437.74 | $1,204,662.13 |
DisclosureSEC source: 0001636178-25-000004 · primarydocument.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,598 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $437.31 to $438.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 7,317 | $436.78 | $3,195,909.75 |
DisclosureSEC source: 0001636178-25-000004 · primarydocument.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,350 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $436.31 to $437.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 6,088 | $435.81 | $2,653,238.68 |
DisclosureSEC source: 0001636178-25-000004 · primarydocument.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,667 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $435.31 to $436.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,679 | $434.96 | $730,301.53 |
DisclosureSEC source: 0001636178-25-000004 · primarydocument.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,755 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $434.31 to $435.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,512 | $433.78 | $655,871.58 |
DisclosureSEC source: 0001636178-25-000004 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,434 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $433.31 to $434.30. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,074 | $432.86 | $464,892.39 |
DisclosureSEC source: 0001636178-25-000004 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,946 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $432.31 to $433.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 98 | $432.09 | $42,344.57 |
DisclosureSEC source: 0001636178-25-000004 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,020 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $431.31 to $432.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 04, 2025 Filed Nov 5, 2025 21:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 21,000 | $146.03 | $3,066,630.00 |
DisclosureSEC source: 0001636178-25-000004 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on August 5, 2025. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 12,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001562180-25-004681 · primarydocument.xml · derivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 12,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 6, 2024. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 300 | $326.81 | $98,042.01 |
DisclosureSEC source: 0001562180-25-004681 · primarydocument.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,118 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 6, 2024. F5 · price: This transaction was executed in multiple trades at prices ranging from $326.57 to $327.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 7,700 | $325.20 | $2,504,068.49 |
DisclosureSEC source: 0001562180-25-004681 · primarydocument.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,418 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 6, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $325.00 to $325.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 100 | $328.28 | $32,828.00 |
DisclosureSEC source: 0001562180-25-004681 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,118 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 6, 2024. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 305 | $326.56 | $99,602.20 |
DisclosureSEC source: 0001562180-25-004681 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,218 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 6, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $326.04 to $326.58. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,595 | $325.44 | $1,169,955.36 |
DisclosureSEC source: 0001562180-25-004681 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,523 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 6, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $325.00 to $325.87. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 12,000 | $117.76 | $1,413,120.00 |
DisclosureSEC source: 0001562180-25-004681 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 6, 2024. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 12,000 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001562180-25-004346 · primarydocument.xml · derivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,500 Underlying: Common Stock · 12,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 6, 2024. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,653 | $326.31 | $865,688.23 |
DisclosureSEC source: 0001562180-25-004346 · primarydocument.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,118 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 6, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $326.00 to $326.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 5,347 | $325.59 | $1,740,928.66 |
DisclosureSEC source: 0001562180-25-004346 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,771 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 6, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $325.00 to $325.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,397 | $326.34 | $455,896.00 |
DisclosureSEC source: 0001562180-25-004346 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,118 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 6, 2024. F4 · price: This transaction was executed in multiple trades at prices ranging from $326.00 to $326.81. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,603 | $325.54 | $847,380.36 |
DisclosureSEC source: 0001562180-25-004346 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,515 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 6, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $325.00 to $325.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 12,000 | $117.76 | $1,413,120.00 |
DisclosureSEC source: 0001562180-25-004346 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on November 6, 2024. F2 · balance_after: Includes 50 shares of common stock acquired on March 4, 2025 under the United Therapeutics Employee Stock Purchase Plan. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 850 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001415889-24-026147 · form4-11052024_041101.xml · derivative · entry 12 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,500 Underlying: Common Stock · 850 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. F3 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 850 stock options, sold 565 of the resulting shares of common stock, and held the remaining 285 shares of common stock. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 817 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-24-026147 · form4-11052024_041101.xml · derivative · entry 11 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 817 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. F2 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 817 stock options, sold 546 of the resulting shares of common stock, and held the remaining 271 shares of common stock. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,400 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001415889-24-026147 · form4-11052024_041101.xml · derivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,350 Underlying: Common Stock · 3,400 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,267 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-24-026147 · form4-11052024_041101.xml · derivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 817 Underlying: Common Stock · 3,267 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 565 | $374.02 | $211,321.30 |
DisclosureSEC source: 0001415889-24-026147 · form4-11052024_041101.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,068 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. F3 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 850 stock options, sold 565 of the resulting shares of common stock, and held the remaining 285 shares of common stock. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 850 | $117.76 | $100,096.00 |
DisclosureSEC source: 0001415889-24-026147 · form4-11052024_041101.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. F3 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 850 stock options, sold 565 of the resulting shares of common stock, and held the remaining 285 shares of common stock. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 546 | $374.02 | $204,214.92 |
DisclosureSEC source: 0001415889-24-026147 · form4-11052024_041101.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,783 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. F2 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 817 stock options, sold 546 of the resulting shares of common stock, and held the remaining 271 shares of common stock. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 817 | $120.26 | $98,252.42 |
DisclosureSEC source: 0001415889-24-026147 · form4-11052024_041101.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. F2 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 817 stock options, sold 546 of the resulting shares of common stock, and held the remaining 271 shares of common stock. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,400 | $374.02 | $1,271,668.00 |
DisclosureSEC source: 0001415889-24-026147 · form4-11052024_041101.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,512 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,400 | $117.76 | $400,384.00 |
DisclosureSEC source: 0001415889-24-026147 · form4-11052024_041101.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,267 | $374.02 | $1,221,923.34 |
DisclosureSEC source: 0001415889-24-026147 · form4-11052024_041101.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,512 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| November 04, 2024 Filed Nov 5, 2024 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,267 | $120.26 | $392,889.42 |
DisclosureSEC source: 0001415889-24-026147 · form4-11052024_041101.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 850 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001415889-24-025696 · form4-10292024_041001.xml · derivative · entry 12 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,750 Underlying: Common Stock · 850 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. F3 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 850 stock options, sold 576 of the resulting shares of common stock, and held the remaining 274 shares of common stock. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 817 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-24-025696 · form4-10292024_041001.xml · derivative · entry 11 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,084 Underlying: Common Stock · 817 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. F2 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 817 stock options, sold 557 of the resulting shares of common stock, and held the remaining 260 shares of common stock. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,400 | $0.00 Strike: $117.76 | $0.00 |
DisclosureSEC source: 0001415889-24-025696 · form4-10292024_041001.xml · derivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,600 Underlying: Common Stock · 3,400 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Options · Derivative | 3,267 | $0.00 Strike: $120.26 | $0.00 |
DisclosureSEC source: 0001415889-24-025696 · form4-10292024_041001.xml · derivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,901 Underlying: Common Stock · 3,267 shares Expires 2026-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 576 | $350.00 | $201,600.00 |
DisclosureSEC source: 0001415889-24-025696 · form4-10292024_041001.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,512 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. F3 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 850 stock options, sold 576 of the resulting shares of common stock, and held the remaining 274 shares of common stock. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 850 | $117.76 | $100,096.00 |
DisclosureSEC source: 0001415889-24-025696 · form4-10292024_041001.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. F3 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 850 stock options, sold 576 of the resulting shares of common stock, and held the remaining 274 shares of common stock. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 557 | $350.00 | $194,950.00 |
DisclosureSEC source: 0001415889-24-025696 · form4-10292024_041001.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,238 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. F2 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 817 stock options, sold 557 of the resulting shares of common stock, and held the remaining 260 shares of common stock. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 817 | $120.26 | $98,252.42 |
DisclosureSEC source: 0001415889-24-025696 · form4-10292024_041001.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. F2 · kind: This option exercise was a "sell-to-cover" transaction whereby the reporting person exercised 817 stock options, sold 557 of the resulting shares of common stock, and held the remaining 260 shares of common stock. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,400 | $350.00 | $1,190,000.00 |
DisclosureSEC source: 0001415889-24-025696 · form4-10292024_041001.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,978 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,400 | $117.76 | $400,384.00 |
DisclosureSEC source: 0001415889-24-025696 · form4-10292024_041001.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,267 | $350.00 | $1,143,450.00 |
DisclosureSEC source: 0001415889-24-025696 · form4-10292024_041001.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,978 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,267 | $120.26 | $392,889.42 |
DisclosureSEC source: 0001415889-24-025696 · form4-10292024_041001.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,245 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 17, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.